Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

Author:

Loi Sherene,Giobbie-Hurder Anita,Gombos Andrea,Bachelot Thomas,Hui Rina,Curigliano Giuseppe,Campone Mario,Biganzoli Laura,Bonnefoi Hervé,Jerusalem Guy,Bartsch Rupert,Rabaglio-Poretti Manuela,Kammler Roswitha,Maibach Rudolf,Smyth Mark J,Di Leo Angelo,Colleoni Marco,Viale Giuseppe,Regan Meredith M,André Fabrice,Fumagalli Debora,Gelber Richard D,Goulioti Theodora,Hiltbrunner Anita,Hui Rita,Roschitzki Heidi,Ruepp Barbara,Boyle Fran,Stahel Rolf,Aebi Stefan,Coates Alan S,Goldhirsch Aron,Karlsson Per,Kössler Ingrid,Fournarakou Stamatina,Gasca Adriana,Pfister Rita,Ribeli-Hofmann Sabrina,Weber Magdelena,Celotto Daniela,Comune Carmen,Frapolli Michela,Sánchez-Hohl Magdalena,Huang Hui,Mahoney Caitlin,Price Karen,Scott Karolyn,Shaw Holly,Fischer Susan,Greco Monica,King Colleen,Andrighetto Stefania,Piccart-Gebhart Martine,Findlay Heather,Jenkins Michelle,Karantza Vassiliki,Mejia Jaime,Schneier Patrick

Publisher

Elsevier BV

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3